SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
MIRM

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$96.13+$0.62 (+0.65%)
 
Market cap
$6.28B
Insider Score
Health Score
Analyst consensus
Listed since
Jul 18, 2019
Market Cap$6.28B+35.5%
Revenue (ttm)$670.78M+42.2%
Net Income-$903.88M-2082.1%
EPS-$15.23-1673.0%
Shares Out65.28M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,062,250
Open$94.50
Previous Close$95.51
Day's Range$94.10 - $98.39
52-Week Range$63.23 - $130.00
Beta0.49
AnalystsBuy
Price Target$155.80(+62.07%)
Earnings DateFeb 24, 2027

About MIRM

Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.

Address
989 East Hillsdale Boulevard, Foster City, CA, 94404, US
Market Cap
6.28 billion
Employees
433
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$15.80M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
11 Buy0 Hold0 SellAvg target $141.88 (+51.2%)

11 firms rating MIRM in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Weak
From MIRM’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
+0.65%
5 Days
+4.17%
1 Month
+15.21%
6 Months
-4.51%
1 Year
+35.45%

$MIRM stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in MIRM holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by MIRM's directors and management

Net Shares Purchased by Insiders−200k−100k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

MIRM Estimated quarterly lobbying spending

Source: U.S. Senate LDA

MIRM Revenue by Segment or Geography

$231.98MTotal
Product sales, net$185.72M80.06%
Stock-based compensation$32.76M14.12%
Acquired IPR&D$13.50M5.82%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New MIRM patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to MIRM from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in MIRM

XBIState Street SPDR S&P Biotech ETF$120.31M
VTIVanguard Morningstar Total Stock Market ETF$119.00M
IWMiShares Russell 2000 ETF$118.89M
VBVanguard Morningstar Small-Cap ETF$105.23M
VBKVanguard Morningstar Small-Cap Growth ETF$58.89M
VXFVanguard Extended Market ETF$53.94M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from MIRM’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
75

News check: Brelovitug achieved second Phase III win with primary endpoint met in AZURE-4; advancing toward BLA filing for hepatitis delta treatment.

Recent Insider Activity

Buys
0
Sells
18
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

-34.0 since Aug 21
0255075100Aug 21 — Insider Score 34.0Aug 22 — Insider Score 33.0Aug 23 — Insider Score 33.0Aug 24 — Insider Score 33.0Aug 25 — Insider Score 33.0Aug 26 — Insider Score 33.0Aug 27 — Insider Score 33.0Aug 28 — Insider Score 33.0Aug 29 — Insider Score 33.0Aug 30 — Insider Score 33.0Aug 31 — Insider Score 33.0Sep 1 — Insider Score 0.0Sep 2 — Insider Score 0.0Sep 3 — Insider Score 0.0Sep 4 — Insider Score 0.0Sep 5 — Insider Score 0.0Sep 6 — Insider Score 0.0Sep 7 — Insider Score 0.0Sep 8 — Insider Score 0.0Sep 9 — Insider Score 0.0Sep 10 — Insider Score 0.0Sep 11 — Insider Score 0.0Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 23.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Aug 21Sep 12Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

LFSCF/M Emerald Life Sciences Innovation ETF3.64%
TDNAT. Rowe Price Biotech ETF1.89%
BBPVirtus Biotech ETF1.22%
XBIState Street SPDR S&P Biotech ETF1.16%
ILDRFirst Trust Innovation Leaders ETF1.01%
BRESBurney U.S. Equity Select ETF0.87%
SCDSJPMorgan Fundamental Data Science Small Core ETF0.45%
AIMSAcuitas Small Cap Active ETF0.43%
BRSMMFS Blended Research Small-Mid Cap ETF0.39%
IBBQInvesco Nasdaq Biotechnology ETF0.39%
EHLSEven Herd Long Short ETF0.39%
ESSCEventide Small Cap ETF0.39%

Weight is the stock’s share of each fund’s holdings.